Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lundbeck And Otsuka In Alzheimer’s Pact
by Rick Mullin
April 1, 2013
| A version of this story appeared in
Volume 91, Issue 13
Denmark’s Lundbeck and Otsuka Pharmaceutical, a Japanese drugmaker, have entered a licensing agreement involving Lundbeck’s Lu AE58054, a selective 5HT6 receptor antagonist, which is being developed as a treatment for Alzheimer’s disease. Under the deal, Lundbeck grants Otsuka codevelopment and co-commercialization rights for Lu AE58054 in North America, Europe, and East Asia, including Japan. Otsuka will pay $150 million up front and as much as $675 million in milestone payments. The companies plan to launch Phase II clinical trials later this year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter